Aspirin use is associated with decreased inpatient mortality in patients with COVID-19: A meta-analysis

Thromboembolism is a major cause of death in patients who suffer from COVID-19. Studies examining the effects of aspirin (ASA) on mortality relating to this phenomenon have showed conflicting results with varying degrees and certainties of evidence. We performed an aggregate data meta-analysis of fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Srinivasan, Aswin, Brown, Jonathan, Krishnamani, Pavitra Parimala, Cornett, Brendon, Kesavan, Ramesh Babu, Sarva, Siva T., Raza, Syed Arman, Kayani, Waleed Tallat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365516/
https://www.ncbi.nlm.nih.gov/pubmed/35971534
http://dx.doi.org/10.1016/j.ahjo.2022.100191
Descripción
Sumario:Thromboembolism is a major cause of death in patients who suffer from COVID-19. Studies examining the effects of aspirin (ASA) on mortality relating to this phenomenon have showed conflicting results with varying degrees and certainties of evidence. We performed an aggregate data meta-analysis of fourteen studies encompassing 164,539 COVID-19 patients, which showed a reduced risk of in-hospital mortality associated with ASA use in eight studies that reported risk ratios (RR 0.90; 95 % CI 0.82–0.98; I(2) = 27.33 %, P = 0.01), six studies that reported hazard ratios (HR 0.56; 95 % CI 0.41–0.76, P ≤ 0.01; I(2) = 85.92 %) and pooled effect size (0.71; 95 % CI 0.59–0.85, P = 0.00, I(2) = 91.51 %). The objective of this study is to report the association between low dose ASA and a reduced risk of in-hospital mortality in patients with COVID-19.

Ejemplares similares